Asset Details
Do you wish to reserve the book?
Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study
Do you wish to request the book?
Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study
2013
Overview
Six patients from the phase 3 trials of zoledronic acid in Paget's disease, who had received zoledronic acid initially and had subsequently relapsed, were entered into an open re-treatment study. Following re-treatment, each patient reached similar absolute nadirs of serum alkaline phosphatase to those recorded after their first dose. No significant adverse events were reported. It is concluded that, while re-treatment of Paget's disease with zoledronic acid is rarely needed, it is safe and effective, with no evidence of treatment resistance based on this small cohort.
Publisher
Nature Publishing Group
We currently cannot retrieve any items related to this title. Kindly check back at a later time.